Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 9

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Systemic scleroderma+3

Recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Artiva Biotherapeutics Inc.

Osteoporosis postmenopausal

Recruiting

Study of Everolimus and Resistance Training to Improve Bone Formation in Healthy Postmenopausal Women

Registered drug
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:Everolimus
  • Sponsor:Odense University Hospital

Systemic lupus erythematosus

Recruiting

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Osteopetrosis

Recruiting

Study of gene-modified stem cells (FT024) in children with TCIRG1-related osteopetrosis using treosulfan, thiotepa, and plerixafor for treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Plerixafor
  • Sponsor:Fondazione Telethon Ets

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GD2IL18CART
  • Sponsor:Universitaet Muenster

Soft tissue necrosis

Recruiting

Evaluating Hyperbaric Oxygen Treatment in Addition to Standard Care for Patients with Necrotizing Soft-Tissue Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Rigshospitalet

Disease risk factor+1

Recruiting

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Instituto De Investigacion Marques De Valdecilla

Congenital pseudarthrosis

Recruiting

Study of NVD003 stem cell implant compared to bone graft for children with congenital pseudarthrosis of the tibia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Autologous Adipose-Derived Stem Cells
  • Sponsor:Novadip Biosciences

Myotonic dystrophy

Recruiting

Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Axial spondyloarthritis+3

Recruiting

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Sint Maartenskliniek Stichting

Axial spondyloarthritis+3

Recruiting

Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Systemic scleroderma

Recruiting

Study of adipose-derived mesenchymal stem cell injections to treat mouth fibrosis in patients with systemic scleroderma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Albumin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.